Onkologie. 2019:13(5):201-204 | DOI: 10.36290/xon.2019.038

Chemotherapy and targeted therapy for bladder cancer

Tomáš Büchler, Aneta Rozsypalová
Onkologická klinika 1. LF UK a Thomayerovy nemocnice, Praha

Chemotherapy is still the dominant modality of systemic treatment for urothelial carcinoma (UC) of the bladder. The single most
important drug in the treatment of UC is cisplatin, usually administered in combination regimens. However, the use of cisplatin
combinations is limited by its marked nephrotoxicity. Although new treatment options have become available with the progress
of immunooncology, satisfactory treatment options do not yet exist for patients progressing after chemotherapy and immunotherapy.
New targeted drugs such as enfortumab vedotin or erdafitinib have shown promiseing results in this setting.

Keywords: urothelial carcinoma, bladder cancer, chemotherapy, targeted therapy

Published: October 20, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Büchler T, Rozsypalová A. Chemotherapy and targeted therapy for bladder cancer. Onkologie. 2019;13(5):201-204. doi: 10.36290/xon.2019.038.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Witjes JA, Bruins M, Cathomas R, et al. Guidelines on Muscle-invasive and Metastatic Bladder Cancer. www: https://uroweb.org/guideline/bladder-cancer-muscle-invasive-and-metastatic/ (Přístup 23. 6. 2019).
    2. Teply BA, Kim JJ. Systemic therapy for bladder cancer - a medical oncologist's perspective. J Solid Tumors. 2014; 4(2): 25-35. Go to original source... Go to PubMed...
    3. Büchler T., Systémová léčba karcinomu močového měchýře, 2016, Urol. praxi 2016; 17(3): 102-105. Go to original source...
    4. Advanced Bladder Cancer Meta-Analysis. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 2005; 48: 202-205. Go to PubMed...
    5. Bladder Cancer. NCCN Guidelines Version 3. 2019. http://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf (Přístup 23. 6. 2019).
    6. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol. 2005; 48: 189-199. Go to PubMed...
    7. Sternberg CN, Skoneczna I, Kerst JM, et al. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol 2015; 16: 76-86. Go to original source... Go to PubMed...
    8. De Santis M, Bellmunt J, Mead G, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 2012; 30: 191-199. Go to original source... Go to PubMed...
    9. Ploussard G, Daneshmand S, Efstathiou JA, et al. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. Eur Urol 2014; 66: 120-137. Go to original source... Go to PubMed...
    10. Stadler WM, Kuzel T, Roth B, et al. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol. 1997; 15: 3394-3398. Go to original source... Go to PubMed...
    11. von der Maase H, Sengelov L, Roberts JT et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005; 23: 4602-4608. Go to original source... Go to PubMed...
    12. Sternberg CN, de Mulder P, Schornagel JH, et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 2006; 42: 50-54. Go to original source... Go to PubMed...
    13. Bellmunt J, Théodore C, Demkov T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009; 27: 4454-4461. Go to original source... Go to PubMed...
    14. Grivas P, Drakaki A, Friedlander TW, Sonpavde G. Conceptual Framework for Therapeutic Development Beyond Anti-PD-1/PD-L1 in Urothelial Cancer. Am Soc Clin Oncol Educ Book. 2019; 39: 284-300. Go to original source... Go to PubMed...
    15. Vlachostergios PJ, Jakubowski CD, Niaz MJ, Lee A, Thomas C, Hackett AL, Patel P, Rashid N, Tagawa ST. Antibody-Drug Conjugates in Bladder Cancer. Bladder Cancer. 2018; 4(3): 247-259. Go to original source... Go to PubMed...
    16. Rosenberg JE, Sridhar SS, Zhang J, et al. Mature results from EV-101: A phase I study of enfortumab vedotin in patients with metastatic urothelial cancer (mUC). J Clin Oncol 2019; 37: (Suppl. 7): 377-377. Go to original source...
    17. Petrylak DP, Balar AV, O'Donnell PH, et al. EV-201: Results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and immune checkpoint inhibitors.J Clin Oncol 2019; 37: (Suppl. 18): 4505-4505. Go to original source...
    18. National Center for Biotechnology Information. PubChem Database. Erdafitinib, CID=67462786, [online] https://pubchem.ncbi.nlm.nih.gov/compound/Erdafitinib (přístup 4. 6. 2019).
    19. FDA Grants Accelerated Approval to Erdafitinib for Metastatic Urothelial Carcinoma, ASCO post, [online], https://www.ascopost.com/News/59934 (přístup 4. 6. 2019).

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.